Pitt Street Research has sent us its thesis on biotech stock, Prescient Therapeutics (ASX:PTX), with a valuation range of 11.6c (bear case) to 16.3c per share (bull case)….

It’s a wrap for the September quarter.  Here are some of the latest highlights from a few ASX small and midcaps on their activities for…

Clinical stage oncology company Prescient Therapeutics will showcase the results of its Phase 1b study in relapsed and refractory T cell lymphomas (TCL) at the largest…

Prescient Therapeutics is on a mission to improve outcomes for cancer patients, and it is making progress with a diverse portfolio of later and early-stage…

It’s the quarterly season again as the ASX market announcements page becomes increasingly flooded with update lodgements. To save you the trouble of trudging through…

Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast. …

Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast….

Telix Pharma (ASX:TLX) announced the US FDA has approved a supplementary New Drug Application (sNDA) for Illuccix, a kit for the preparation of gallium Ga 68 gozetotide…

The granting of an Orphan Drug Designation for PTX-100 gives Prescient guaranteed market exclusivity of 7 years. The US FDA has just granted Prescient Therapeutics (ASX:PTX)’s…